Myasthenia gravis: pathogenesis, diagnosis, and therapy.

Area of Science:

• Neurology
• Immunology

Background:

• Myasthenia gravis (MG) primarily impacts ocular muscles, characterized by abnormal fatigability.
• MG is increasingly recognized as an autoimmune disorder involving thymus-derived antibodies.
• Associations between MG and other autoimmune conditions are well-documented.

Purpose of the Study:

• To outline the diagnostic approach for myasthenia gravis.
• To review current therapeutic strategies for myasthenia gravis.

Main Methods:

• Clinical examination highlighting abnormal fatigability.
• Diagnostic confirmation through anticholinesterase administration response and electromyography (EMG) with repetitive nerve stimulation.
• Assessment of treatment efficacy for various therapeutic options.

Main Results:

• Anticholinesterase drug administration typically yields a rapid and reproducible diagnostic response.
• EMG findings in myasthenic muscles evoked by repetitive peripheral motor nerve stimulation are definitive for diagnosis.
• Treatment strategies include anticholinesterase drugs as primary therapy, thymectomy for specific cases, and steroid therapy for refractory patients.

Conclusions:

• A high index of suspicion is crucial for diagnosing myasthenia gravis.
• Anticholinesterase drugs are the cornerstone of MG treatment.
• Surgical and steroid-based therapies offer alternatives for patients with thymoma, severe disease, or poor response to initial treatments.